MedTrace Logo

Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)

NCT04811339 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-03-01

Study results available
· View outcomes & findings →

Summary

The Center for Disease Control (CDC) and World Health Organization (WHO) have deemed the COVID-19 virus a global pandemic of unprecedented severity in modern times. In 2019, this novel Coronavirus (COVID-19) emerged from the Asian continent and has now caused upwards of 1million deaths and over 6 million infections globally. Currently, the estimated global economic impact is over 5 Trillion dollars. Understanding the host response to pathogens, specifically the cellular and humoral responses, has played an important role in new non-antibiotic therapies. Bismuth subsalicylate (Pepto-Bismol) has a potential role in the clearance and/or recurrence of enteric viral infections.

Conditions

Interventions

DRUG

Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable

Pepto bismol (bismuth subsalicylate)

OTHER

Placebo oral tablet without BSS

Placebo Tablet made by P \& G to contain everything except active ingredient ( BSS)

Sponsors & Collaborators

  • Procter and Gamble

    collaborator INDUSTRY

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Bruce Yacyshyn, MD · Adjunct Professor Systems Physiology and Pharmacology University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-27
Primary Completion
2021-08-15
Completion
2021-08-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811339 on ClinicalTrials.gov